0740 GMT - Novo Nordisk's investor day underwhelmed on multiple fronts, relative to some of the more optimistic expectations heading into the event, Deutsche Bank analyst Emmanuel Papadakis writes. "Whilst the event provided both a helpful and thorough review of the business outlook as well as a strategic refresh, it was met with a fairly punishing market response." The bank says there was largely a reiteration of familiar strategic messaging and the mid-term building blocks, in addition to somewhat underwhelming mid-term guidance. There was also nothing of substance in terms of clinical data or assets, and little clarity on M&A even though it clearly remains on the agenda, Deutsche Bank adds. The bank lowers its stock target price to 245 Danish kroner from 265 kroner and retains its sell rating. Shares fall 0.6% to 258.50 kroner.